Global Artificial Intelligence (AI) in Cancer Market Growth (Status and Outlook) 2026-2032
Description
The global Artificial Intelligence (AI) in Cancer market size is predicted to grow from US$ 2353 million in 2025 to US$ 8085 million in 2032; it is expected to grow at a CAGR of 19.3% from 2026 to 2032.
Artificial Intelligence (AI) in Cancer refers to the application of machine learning, deep learning, and data-driven computational models across the oncology care continuum to support cancer screening, diagnosis, treatment planning, and outcome prediction. AI systems in oncology analyze large volumes of heterogeneous data, including medical imaging, digital pathology slides, genomic and multi-omics data, and real-world clinical records, to detect patterns that exceed human cognitive limits. In clinical practice, these solutions function primarily as decision-support tools, improving diagnostic accuracy, standardizing interpretation, accelerating workflows, and enabling more personalized treatment strategies. Rather than replacing oncologists, AI augments clinical expertise by reducing variability and supporting earlier and more consistent cancer detection and management.
From a multi-angle classification and parameterization perspective, the market can be segmented by clinical application stage (screening and early detection, diagnosis and classification, treatment planning, therapy monitoring, and prognosis), by data modality (imaging-based, pathology-based, genomics-based, clinical data-driven, or multimodal fusion), and by cancer type (lung, breast, colorectal, prostate, hematologic, and rare cancers). Additional parameters that differentiate solutions include sensitivity and specificity at defined clinical thresholds, explainability of AI outputs, integration with hospital IT systems, regulatory clearance status, and scalability across institutions and geographies.
The industry value chain begins upstream with data generation and infrastructure providers, including imaging equipment manufacturers, sequencing platforms, digital pathology scanners, and cloud computing services. Midstream players consist of AI oncology solution developers that curate datasets, train models, and package algorithms into regulated software or integrated platforms. Downstream customers include hospitals, cancer centers, diagnostic laboratories, pharmaceutical companies, and population-level screening programs, often adopting AI tools through enterprise licenses or software-as-a-service models.
From a profitability standpoint, AI in Cancer solutions typically exhibit gross margins in the 65–85% range, reflecting their software-centric economics once development and regulatory costs are absorbed. Cloud-based platforms and AI-as-a-service models tend to achieve the highest margins, while device-embedded solutions trade some margin for faster adoption through OEM partnerships. Market growth is driven by rising cancer incidence, shortages of oncology specialists, increasing data complexity, and the shift toward precision medicine. Key trends include multimodal data integration, expansion from detection to outcome prediction, deeper OEM and hospital integration, and growing use of AI to support value-based oncology care.
LPI (LP Information)' newest research report, the “Artificial Intelligence (AI) in Cancer Industry Forecast” looks at past sales and reviews total world Artificial Intelligence (AI) in Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Artificial Intelligence (AI) in Cancer sales for 2026 through 2032. With Artificial Intelligence (AI) in Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Artificial Intelligence (AI) in Cancer industry.
This Insight Report provides a comprehensive analysis of the global Artificial Intelligence (AI) in Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Artificial Intelligence (AI) in Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Artificial Intelligence (AI) in Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Artificial Intelligence (AI) in Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Artificial Intelligence (AI) in Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Artificial Intelligence (AI) in Cancer market by product type, application, key players and key regions and countries.
Segmentation by Type:
Medical Imaging–based AI
Digital Pathology–based AI
Genomics & Multi-omics AI
Others
Segmentation by AI Function Depth:
Detection & Flagging
Segmentation & Quantification
Classification & Grading
Prediction & Outcome Modeling
Others
Segmentation by Product Form & Commercial Model:
Device-embedded AI Systems
Standalone Software / SaaS Platforms
AI-as-a-Service for Oncology
Others
Segmentation by Application:
Lung Cancer
Breast Cancer
Colorectal & GI Cancers
Prostate & Urological Cancers
Hematologic & Rare Cancers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
PathAI
PaigeAI
Lunit
INFERVISION TECHNOLOGY
Aidoc
VUNO, Inc.
ANNALISE-AI PTY LTD
BioMind
YITU Technology
Shukun Technology
Beijing Huiyi Huiying Medical Technology
Shenzhen Keya Medical Technology
Densitas
Volpara
Niramai
MVision AI
MammoScreen
Perimeter Medical Imaging AI
ICAD
LungLifeAI
Nanox.AI
Varian Medical Systems
Canon Medical
GE Healthcare
Philips
Please note: The report will take approximately 2 business days to prepare and deliver.
Artificial Intelligence (AI) in Cancer refers to the application of machine learning, deep learning, and data-driven computational models across the oncology care continuum to support cancer screening, diagnosis, treatment planning, and outcome prediction. AI systems in oncology analyze large volumes of heterogeneous data, including medical imaging, digital pathology slides, genomic and multi-omics data, and real-world clinical records, to detect patterns that exceed human cognitive limits. In clinical practice, these solutions function primarily as decision-support tools, improving diagnostic accuracy, standardizing interpretation, accelerating workflows, and enabling more personalized treatment strategies. Rather than replacing oncologists, AI augments clinical expertise by reducing variability and supporting earlier and more consistent cancer detection and management.
From a multi-angle classification and parameterization perspective, the market can be segmented by clinical application stage (screening and early detection, diagnosis and classification, treatment planning, therapy monitoring, and prognosis), by data modality (imaging-based, pathology-based, genomics-based, clinical data-driven, or multimodal fusion), and by cancer type (lung, breast, colorectal, prostate, hematologic, and rare cancers). Additional parameters that differentiate solutions include sensitivity and specificity at defined clinical thresholds, explainability of AI outputs, integration with hospital IT systems, regulatory clearance status, and scalability across institutions and geographies.
The industry value chain begins upstream with data generation and infrastructure providers, including imaging equipment manufacturers, sequencing platforms, digital pathology scanners, and cloud computing services. Midstream players consist of AI oncology solution developers that curate datasets, train models, and package algorithms into regulated software or integrated platforms. Downstream customers include hospitals, cancer centers, diagnostic laboratories, pharmaceutical companies, and population-level screening programs, often adopting AI tools through enterprise licenses or software-as-a-service models.
From a profitability standpoint, AI in Cancer solutions typically exhibit gross margins in the 65–85% range, reflecting their software-centric economics once development and regulatory costs are absorbed. Cloud-based platforms and AI-as-a-service models tend to achieve the highest margins, while device-embedded solutions trade some margin for faster adoption through OEM partnerships. Market growth is driven by rising cancer incidence, shortages of oncology specialists, increasing data complexity, and the shift toward precision medicine. Key trends include multimodal data integration, expansion from detection to outcome prediction, deeper OEM and hospital integration, and growing use of AI to support value-based oncology care.
LPI (LP Information)' newest research report, the “Artificial Intelligence (AI) in Cancer Industry Forecast” looks at past sales and reviews total world Artificial Intelligence (AI) in Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Artificial Intelligence (AI) in Cancer sales for 2026 through 2032. With Artificial Intelligence (AI) in Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Artificial Intelligence (AI) in Cancer industry.
This Insight Report provides a comprehensive analysis of the global Artificial Intelligence (AI) in Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Artificial Intelligence (AI) in Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Artificial Intelligence (AI) in Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Artificial Intelligence (AI) in Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Artificial Intelligence (AI) in Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Artificial Intelligence (AI) in Cancer market by product type, application, key players and key regions and countries.
Segmentation by Type:
Medical Imaging–based AI
Digital Pathology–based AI
Genomics & Multi-omics AI
Others
Segmentation by AI Function Depth:
Detection & Flagging
Segmentation & Quantification
Classification & Grading
Prediction & Outcome Modeling
Others
Segmentation by Product Form & Commercial Model:
Device-embedded AI Systems
Standalone Software / SaaS Platforms
AI-as-a-Service for Oncology
Others
Segmentation by Application:
Lung Cancer
Breast Cancer
Colorectal & GI Cancers
Prostate & Urological Cancers
Hematologic & Rare Cancers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
PathAI
PaigeAI
Lunit
INFERVISION TECHNOLOGY
Aidoc
VUNO, Inc.
ANNALISE-AI PTY LTD
BioMind
YITU Technology
Shukun Technology
Beijing Huiyi Huiying Medical Technology
Shenzhen Keya Medical Technology
Densitas
Volpara
Niramai
MVision AI
MammoScreen
Perimeter Medical Imaging AI
ICAD
LungLifeAI
Nanox.AI
Varian Medical Systems
Canon Medical
GE Healthcare
Philips
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
143 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Artificial Intelligence (AI) in Cancer Market Size by Player
- 4 Artificial Intelligence (AI) in Cancer by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Artificial Intelligence (AI) in Cancer Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
